|
1.
|
|
19 p, 1.5 MB |
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
/
Wieduwilt, M.J. (University of Oklahoma) ;
Metheny, L. (University Hospitals Seidman Cancer Center) ;
Zhang, M.J. (Medical College of Wisconsin) ;
Wang, H.L. (Center for International Blood and Marrow Transplant Research) ;
Estrada-Merly, N. (Center for International Blood and Marrow Transplant Research) ;
Marks, D.I. (University Hospitals Bristol National Health Service Trust) ;
Samer Al-Homsi, A. (New York University Langone Health) ;
Muffly, L. (Stanford University) ;
Chao, N. (Duke University Medical Center) ;
Rizzieri, D. (Duke University) ;
Gale, R.P. (Imperial College London) ;
Gadalla, S.M. (National Institutes of Health) ;
Cairo, M. (New York Medical College) ;
Mussetti, Alberto (Institut d'Investigacio Biomedica de Bellvitge) ;
Gore, S. (Yale New Haven Hospital) ;
Bhatt, V.R. (University of Nebraska Medical Center) ;
Patel, S.S. (University of Utah) ;
Michelis, F.V. (Princess Margaret Cancer Centre) ;
Inamoto, Y. (National Cancer Center Hospital) ;
Badawy, S.M. (Northwestern University Feinberg School of Medicine) ;
Copelan, E. (Atrium Health) ;
Palmisiano, N. (Thomas Jefferson University) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Lazarus, H.M. (Case Western Reserve University) ;
Ganguly, S. (University of Kansas Health System) ;
Bredeson, C. (The Ottawa Hospital Transplant and Cellular Therapy Program) ;
Perez, M.A.D. (Hospital Infantil Universitario Niño Jesus) ;
Cassaday, R. (University of Washington) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Ballen, K. (Division of Hematology/Oncology. University of Virginia Health System) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Wirk, B. (Penn State Cancer Institute) ;
Bacher, U. (University of Bern) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Bashey, A. (Northside Hospital) ;
Murthy, H.S. (Mayo Clinic) ;
Yared, J.A. (University of Maryland) ;
Aldoss, I. (City of Hope Medical Center) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Liu, H. (University of Chicago Medicine) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Waller, E.K. (Emory University) ;
Solh, M. (Northside Hospital) ;
Seftel, M.D. (University of British Columbia) ;
van der Poel, M. (Maastricht University Medical Center) ;
Grunwald, M.R. (Atrium Health) ;
Liesveld, J.L. (University of Rochester Medical Center) ;
Kamble, R.T. (Baylor College of Medicine) ;
McGuirk, J. (University of Kansas Health System) ;
Munker, R. (University of Kentucky) ;
Cahn, Jean-Yves (Universite Grenoble Alpes) ;
Lee, J.W. (The Catholic University of Korea) ;
Freytes, C.O. (University of Texas Health Science Center) ;
Krem, M.M. (University of Kentucky) ;
Winestone, L.E. (University of California) ;
Gergis, U. (Thomas Jefferson University) ;
Nathan, S. (Rush University Medical Center) ;
Olsson, R.F. (Karolinska Institutet) ;
Verdonck, L.F. (Isala Clinic) ;
Sharma, A. (St. Jude Children's Research Hospital) ;
Ringden, O. (Karolinska Institutet) ;
Friend, B.D. (Baylor College of Medicine) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Chhabra, S. (Center for International Blood and Marrow Transplant Research) ;
Nishihori, T. (Moffitt Cancer Center) ;
Seo, S. (Dokkyo Medical University) ;
George, B. (Christian Medical College) ;
Baxter-Lowe, L.A. (Children's Hospital Los Angeles) ;
Hildebrandt, G.C. (University of Kentucky) ;
de Lima, M. (University Hospitals Case Medical Center) ;
Litzow, M. (Mayo Clinic Rochester) ;
Kebriaei, P. (The University of Texas MD Anderson Cancer Center) ;
Hourigan, C.S. (National Institutes of Health) ;
Abid, M.B. (Medical College of Wisconsin) ;
Weisdorf, D.J. (University of Minnesota) ;
Saber, W. (Center for International Blood and Marrow Transplant Research) ;
Universitat Autònoma de Barcelona
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. [...]
2022 -  10.1182/bloodadvances.2021004916
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 339-357
|
|
|
2.
|
|
20 p, 1.9 MB |
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
/
Menghrajani, Kamal (Leukemia Service) ;
Gomez-Arteaga, Alexandra (Memorial Sloan Kettering Cancer Center) ;
Madero-Marroquin, Rafael (Icahn School of Medicine. Mount Sinai St Luke's and Mount Sinai West) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Bo-Subait, Khalid (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Sanchez, Jonathan (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Wang, Hai-Lin (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Assal, Amer (Columbia University Irving Medical Center) ;
Bacher, Vera Ulrike (Bern University Hospital) ;
Badawy, Sherif M. (Northwestern University Feinberg School of Medicine) ;
Bejanyan, Nelli (Department of Blood and Marrow Transplant and Cellular Immunotherapy. Moffitt Cancer Center) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Bredeson, Christopher (Ottawa Hospital Research Institute) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Castillo, Paul (UF Health Shands Children's Hospital) ;
Cerny, Jan (University of Massachusetts Medical Center) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Ciurea, Stefan Octavian (The University of Texas MD Anderson Cancer Center) ;
DeFilipp, Zachariah (Massachusetts General Hospital) ;
Farhadfar, Nosha (Division of Hematology/Oncology. University of Florida College of Medicine) ;
Gadalla, Shahinaz (Division of Cancer Epidemiology and Genetics. National Cancer Institute (NCI) Clinical Genetics Branch. National Institutes of Health (NIH)) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (Division of Hematological Malignancy and Cellular Therapeutics. University of Kansas Health System) ;
Gowda, Lohith (Section of Hematology. Department of Medicine. Yale University School of Medicine. Yale Comprehensive Cancer Center. Yale New Haven Hospital) ;
Grunwald, Michael R. (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health) ;
Hashmi, Shahrukh (Oncology Center. King Faisal Specialist Hospital and Research Center) ;
Hildebrandt, Gerhard (Markey Cancer Center. University of Kentucky) ;
Kanakry, Christopher G. (Experimental Transplantation and Immunology Branch. Center for Cancer Research. NCI. NIH) ;
Kansagra, Ankit (UT Southwestern Medical Center. Blood and Marrow Transplant Program) ;
Khimani, Farhad (H Lee Moffitt Cancer Center and Research Institute) ;
Krem, Maxwell (Markey Cancer Center. University of Kentucky College of Medicine) ;
Lazarus, Hillard (Department of Medicine. University Hospitals Case Medical Center. Seidman Cancer Center. Case Comprehensive Cancer Center. Case Western Reserve University) ;
Liu, Hongtao (Section of Hematology/Oncology. University of Chicago Medicine) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Michelis, Fotios V. (Allogeneic Blood and Marrow Transplant Program. Princess Margaret Cancer Centre) ;
Nathan, Sunita (Section of Bone Marrow Transplant and Cell Therapy. Rush University Medical Center) ;
Nishihori, Taiga (The Fred and Pamela Buffett Cancer Center. University of Nebraska Medical Center) ;
Olsson, Richard (Centre for Clinical Research Sormland. Uppsala University) ;
Reshef, Ran (Columbia Center for Translational Immunology. Columbia University Medical Center) ;
Rizzieri, David (Division of Hematologic Malignancies and Cellular Therapy. Duke University) ;
Rowe, Jacob M. (Department of Hematology. Shaare Zedek Medical Center) ;
Savani, Bipin N. (Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Solh, Melhem (The Blood and Marrow Transplant Group of Georgia. Northside Hospital) ;
Ustun, Celalettin (Hematology. Oncology. and Cell Therapy. Rush University Medical Center) ;
Verdonck, Leo F. (Department of Hematology and Oncology. Isala Clinic) ;
Hourigan, Christopher (National Heart Lung. and Blood Institute. NIH) ;
Sandmaier, Brenda (Clinical Research Division. Fred Hutchinson Cancer Research Center) ;
Litzow, Mark (Division of Hematology and Transplant Center. Mayo Clinic Rochester) ;
Kebriaei, Partow (Department of Stem Cell Transplantation. Division of Cancer Medicine. The University of Texas MD Anderson Cancer Center) ;
Weisdorf, Daniel (Division of Hematology. Oncology and Transplantation. Department of Medicine. University of Minnesota) ;
Zhang, Yanming (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Tallman, Martin S. (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. [...]
2022 - 10.1182/bloodadvances.2021004881
Blood advances, Vol. 6 Núm. 3 (august 2022) , p. 828-847
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
